Gilead Sciences (GILD) and Forty Seven (FTSV) acquisition information, including expected completion date and offer price, is displayed in the merger details table below.
This deal was successfully consummated on April 7, 2020
The major Gilead Sciences (GILD) and Forty Seven (FTSV) buyout news updates & events are listed below. An invaluable data source for traders & investors looking to familiarize themselves with the Gilead Sciences (GILD) takeover of Forty Seven (FTSV) and trade the risk arbitrage spread. Following the acquisition news and events section, there are in-depth company profiles.
Receive instant FREE access to constantly updated FTSV news related to the current merger deal. Simply register by entering your email address to receive weekly publication updates. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, click Forty Seven (FTSV). Proprietary commentary can also be accessed by simply entering a ticker symbol into the search box in the menu bar above such as “FTSV“, or clicking on a stock ticker in the tag cloud at the foot of this article.
Traders can also review similar deal information on current takeover stocks by selecting deals from the “Deal” menu item above or “Closed Deals” for previous buyouts. For broader merger and acquisition news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
Forty Seven (NASDAQ: FTSV) Merger - Acquisition News and Events
Forty Seven Company Profile
Forty Seven, Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.
Forty Seven, Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin’s lymphoma; and collaboration with Acerta Pharma to evaluate novel immuno-oncology triple combination in diffuse large B-Cell Lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven, Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
